Business Wire

JEOL: Launch of the New Benchtop Scanning Electron Microscope “JCM-7000Plus NeoScope™”

1.9.2026 09:30:00 CEST | Business Wire | Press release

Share

JEOL Ltd. (President & CEO: Izumi Oi) has developed the benchtop scanning electron microscope (SEM) “JCM-7000Plus” and will begin sales on September 1, 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825564112/en/

JCM-7000Plus NeoScope™

[Development Background]

Benchtop scanning electron microscopes are increasingly used in fields including electrical and electronics, automotive and machinery, steel and metals, chemical and pharmaceuticals. They are utilized not only in research and development but also in manufacturing-related applications, such as quality control and product inspection. In addition, they are adopted in educational settings at middle and high schools as well as universities. Given these diverse applications, there is growing demand for improved operational efficiency, simpler and more automated operation, and enhanced observation, analysis, and measurement performance.

To meet these needs, we have expanded the landing voltage (accelerating voltage) to 20 kV. This has improved resolution to 6 nm, enabling measurements at higher magnification.

On the software side, the new JCM-7000Plus retains the simple, user-friendly GUI of the current JCM-7000, including Zeromag, which enables a seamless transition from optical imaging to SEM observation, and the Live Analysis function, which allows real-time elemental analysis during observation. It also adds the enhanced automation feature Neo Action.

In addition to the three existing Live functions (Live Analysis, Live Map, and Live 3D), we have added two new features: Live Particle, which automatically measures particle size and count in real time while observing, and Live Report, which automatically acquires data and generates reports while moving the field of view, a feature available in high-end FE-SEMs. These features simplify routine tasks, making them more intuitive and efficient while significantly supporting users' analytical workflows.

[Main Features]

1. Expanding landing voltage to 20 kV for improved resolution (secondary electron image: 6 nm, backscattered electron image: 8 nm)

2. Improved backscattered electron detector for enhanced image quality

3. New Live Particle function automatically measures particle size and count, simplifying workflow

4. Live Report enables data acquisition and report creation while moving the field of view, improving work efficiency

5. Simple and user-friendly GUI retained, with added automation functions for more intuitive and easier operation

[Sales target]

300 units/year

[Related link]

Product Information: JCM-7000Plus NeoScope™ Benchtop SEM
https://www.jeol.com/products/scientific/sem/jcm-7000plus.php

View source version on businesswire.com: https://www.businesswire.com/news/home/20260825564112/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PPMI and Alipay+ Expand QR Ph for Cross-Border Commerce, Connecting Filipino Businesses with Global Consumers1.9.2026 09:25:00 CEST | Press release

Partnership significantly expands cross-border connectivity, supporting Philippines’ digitalisation ambitions and opening new opportunities for 2.5M local merchants and SMEsAlipay+ connects with 10+ national payment schemes across Asia, Middle East and Latin America The Philippine Payments Management, Inc. (PPMI) and Ant International's unified wallet gateway, Alipay+, have officially enabled Alipay+ on QR Ph, seamlessly connecting the nation's digital payments ecosystem with global commerce. This milestone is in alignment with and supports the Bangko Sentral ng Pilipinas' (BSP) digital payments transformation goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901759507/en/ (L-R) Danny Chung, General Manager of Alipay+ Global Growth Center, Ant International; Carmelita “Melit” Araneta, General Manager of Philippine Payments Management Inc.; Atty. Bridget Rose M. Mesina-Romero, Director, Payments Policy and Development

Global Tech Sales Forecast to Reach $1.4 Trillion in 2026, Even as 56% of Consumers Delay Purchases, NIQ Finds1.9.2026 09:00:00 CEST | Press release

Global study finds price-sensitive shoppers will still pay more when products deliver clear, lasting benefits Global sales of consumer technology and durable goods are forecast to reach $1.4 trillion in 2026, up 5.1% year over year, even as 56% of consumers say they have delayed a technology purchase because of price or while waiting for a discount, according to new research from NIQ (NYSE: NIQ), the Official Global Insights Partner of IFA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901758503/en/ The era of automatic tech & durables upgrades is over. Released ahead of IFA 2026, which kicks off in Berlin on Sept. 4, 2026, NIQ today released its annual “State of Tech & Durables” report. Consumer Tech Trends 2027: How to Win When Every Purchase Must Be Justified examines how years of economic volatility have transformed technology purchasing behavior and what manufacturers and retailers must do to remain competitive. Key

Searchlight Capital Partners Announces Investment in Aderian Group1.9.2026 09:00:00 CEST | Press release

Partnership will support Aderian’s continued growth and expansion across the Nordic region Searchlight Capital Partners, L.P. ("Searchlight"), a leading global private investment firm, today announced an investment in Aderian Group ("Aderian" or the "Company"), a Nordic managed IT services provider serving more than 10,000 small and medium-sized enterprise ("SME") customers throughout Sweden and Norway. As part of the transaction, Aderian's management team will reinvest in the Company and remain meaningful shareholders alongside Searchlight, underscoring their continued commitment to Aderian's long-term growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901430715/en/ Aderian provides cloud, cybersecurity, AI and analytics, networking and modern workplace solutions. Since its founding in 2022, the Company has grown to approximately SEK 2.5 billion in revenue, with more than 850 employees and over 10,000 SME customers a

FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities1.9.2026 09:00:00 CEST | Press release

New license agreement enables an integrated workflow combining antibody labeling, human-relevant 3D testing and quantitative imaging for antibody-based therapeutics Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases and FluoSphera, a Swiss biotechnology company developing advanced in vitro platforms to improve the prediction of drug efficacy and safety, today announced a new license agreement for use of AbYlink™, Debiopharm’s proprietary antibody conjugation technology. The agreement enables FluoSphera to offer biotechnology and pharmaceutical companies an integrated workflow combining regio-selective antibody labeling, high-throughput testing in human-relevant three-dimensional models and quantitative imaging analysis. The new offering is designed to support the characterization of antibody-drug conjugates (ADCs), bispecific antibodies, therape

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 08:30:00 CEST | Press release

Approval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years Second approval for Enhertu in the EU in two months Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results fro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye